Effects of the combination of TRC105 and bevacizumab on endothelial cell biology

por Liu, Yingmiao, Tian, Hongyu, Blobe, Gerard C., Theuer, Charles P., Hurwitz, Herbert I., Nixon, Andrew B.
Publicado 2014

Therapeutic effect of TRC105 and decitabine combination in AML xenografts

por Baik, June, Felices, Martin, Yingst, Ashley, Theuer, Charles P., Verneris, Michael R., Miller, Jeffrey S., Perlingeiro, Rita
Publicado 2020

In Vivo Tumor-Targeted Dual-Modality PET/Optical Imaging with a Yolk/Shell-Structured Silica Nanosystem

por Shi, Sixiang, Chen, Feng, Goel, Shreya, Graves, Stephen A., Luo, Haiming, Theuer, Charles P., Engle, Jonathan W., Cai, Weibo
Publicado 2018

In Vivo Tumor Vasculature Targeted PET/NIRF Imaging with TRC105(Fab)-Conjugated, Dual-Labeled Mesoporous Silica Nanoparticles

por Chen, Feng, Nayak, Tapas R., Goel, Shreya, Valdovinos, Hector F., Hong, Hao, Theuer, Charles P., Barnhart, Todd E., Cai, Weibo
Publicado 2014

Engineering of Hollow Mesoporous Silica Nanoparticles for Remarkably Enhanced Tumor Active Targeting Efficacy

por Chen, Feng, Hong, Hao, Shi, Sixiang, Goel, Shreya, Valdovinos, Hector F., Hernandez, Reinier, Theuer, Charles P., Barnhart, Todd E., Cai, Weibo
Publicado 2014

Theranostic Unimolecular Micelles Based on Brush-Shaped Amphiphilic Block Copolymers for Tumor-Targeted Drug Delivery and Positron Emission Tomography Imaging

por Guo, Jintang, Hong, Hao, Chen, Guojun, Shi, Sixiang, Nayak, Tapas R., Theuer, Charles P., Barnhart, Todd E., Cai, Weibo, Gong, Shaoqin
Publicado 2014

In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine

por Chen, Feng, Hong, Hao, Goel, Shreya, Graves, Stephen A., Orbay, Hakan, Ehlerding, Emily B., Shi, Sixiang, Theuer, Charles P., Nickles, Robert J., Cai, Weibo
Publicado 2015

Engineering Intrinsically Zirconium‐89 Radiolabeled Self‐Destructing Mesoporous Silica Nanostructures for In Vivo Biodistribution and Tumor Targeting Studies

por Goel, Shreya, Chen, Feng, Luan, Shijie, Valdovinos, Hector F., Shi, Sixiang, Graves, Stephen A., Ai, Fanrong, Barnhart, Todd E., Theuer, Charles P., Cai, Weibo
Publicado 2016

Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer

por Liu, Yingmiao, Starr, Mark D, Brady, John C, Dellinger, Andrew, Pang, Herbert, Adams, Bonne, Theuer, Charles P, Lee, Nam Y, Hurwitz, Herbert I, Nixon, Andrew B
Publicado 2014

Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial

por Ahluwalia, Manmeet S., Rogers, Lisa R., Chaudhary, Rekha, Newton, Herbert, Ozair, Ahmad, Khosla, Atulya A., Nixon, Andrew B., Adams, Bonne J., Seon, Ben K., Peereboom, David M., Theuer, Charles P.
Publicado 2023

A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer

por Vaklavas, Christos, Stringer-Reasor, Erica M., Elkhanany, Ahmed M., Ryan, Kevin J., Li, Yufeng, Theuer, Charles P., Acosta, Edward P., Wei, Shi, Yang, Eddy S., Grizzle, William E., Forero-Torres, Andres
Publicado 2023